Mitochondrial Disease Testing with CentoMito®
Improve the lives of patients of all ages affected by mitochondrial diseases. Mitochondrial diseases are genetic conditions that occur when mitochondria fail to produce enough energy for the cell.
Establishing a Diagnosis As Soon as Possible
There is no cure for mitochondrial diseases, but several different treatment options and approaches can help reduce symptoms or delay or prevent the progression of the disease. CentoMito is CENTOGENE's targeted genetic testing for the diagnosis of mitochondrial diseases.
With CentoMito CENTOGENE has designed a special panel for diagnostics of mitochondrial diseases. By targeting nuclear encoded genes as well as mitochondrial encoded genes, this panel provides a comprehensive test in patients with a demonstrated mitochondrial deficiency on biopsy material or a suspicion of mitochondrial disorders based on the patient’s symptoms.
Why Choose CENTOGENE?
Distinctive product offering centered around high-quality genetic testing
Strong presence in and access to countries with a high prevalence of rare diseases
CentoCard provides easy logistics for central testing
Rare disease-centric Bio/Databank generates best-in-class medical insights
Deep expertise in rare, metabolic, and neurodegenerative diseases, as well as multiomics enables better diagnostics
What Tests for Diagnostics of Mitochondrial Diseases Are Offered by CENTOGENE?
CENTOGENE Offers Two Panels for the Diagnostics of Mitochondrial Diseases:
CentoMito® Comprehensive
Covers the entire mitochondrial genome (CentoMito® Genome) along with nuclear genes related to mitochondrial diseases (≥99.0% targeted regions covered at ≥20x).
CentoMito® Genome
Covers all mitochondrial encoded genes (≥97.0% targeted regions covered at ≥200x). Includes NGS-based copy number variation analysis. ≥5% mitochondrial heteroplasmy can be confidently detected.
What Are Mitochondrial Diseases?
Mitochondrial diseases are genetic conditions that occur when mitochondria fail to produce enough energy for the cell.
Genetic mutations in the mitochondrial genome, or nuclear genes, encoding proteins that maintain the function of the mitochondria, causing symptoms mainly in the organs where energy consumption is high. These organs are eye, liver, kidney, pancreas, blood, inner ear, colon, skeletal muscle, heart and brain.
Mitochondrial diseases are estimated to affect 1 in 5,000–8,500 people.
Who Should Get Tested for Mitochondrial Diseases?
- Individuals with clinical symptoms characteristic of a specific mitochondrial disorder such as progressive external ophthalmoplegia, muscle biopsy findings, stroke-like episodes, etc.
- Individuals with any progressive multisystem disorder of unknown etiology
- Individuals with multiple complex neurologic features or a single neurological symptom with other system involvement
- Children presenting with lactic acidosis
- Presymptomatic testing for at-risk family members
Test Results
- Positive result – indicates that a previously understood disease-causing mutation was identified. This result can help the physician to assess the risk of experiencing certain symptoms and indicate the best way how to treat the disease. Positive result may also identify family members at risk of having the mutation, and carrier testing may be recommended.
- Negative result – does not necessarily rule out a mitochondrial disorder, and the patient should be managed according to clinical symptoms. Possible reasons for a negative result could be that the patient may have a mutation in a gene not covered by the testing panel, or it could be a mutation which is not detectable with the performed test, or the patient does not have a mitochondrial disorder.
- Variant of unknown clinical significance (VUS) – indicates that we have identified a change in the DNA, but this change is not known to be associated with a disorder. To clarify the clinical significance of the variant, testing other family members may be helpful.
Resources
Scientific Publications
Innovative Treatment of a Severe Disease
Exploratory innovative treatments are often pursued and justified in diseases that are associated with fatal outcomes in early childhood. CENTOGENE is proud to have contributed to a pertinent success […]
Related Webinars
Niemann-Pick tipo C: Dos genes – muchos cuadros clínicos – un biomarcador unificador
Mira nuestro webinar sobre Niemann-Pick tipo C, un raro trastorno genético progresivo caracterizado por la incapacidad del cuerpo para transportar el colesterol y otras sustancias grasas (lípidos) […]
Niemann-Pick Type C: Two Genes - Many Clinical Pictures - One Unifying Biomarker
Watch our webinar “Niemann-Pick type C: Two Genes – Many Clinical Pictures – One Unifying Biomarker” hosted by Prof. Peter Bauer. Throughout the webinar, he will provide an overview of this rare […]
CentoLCV – El nuevo estándar para detectar desequilibrios cromosómicos
Mira el webinar sobre CentoLCV™, nuestro nuevo análisis integral de variación de número de copias (CNV), y aprender por qué es el nuevo estándar para establecer diagnósticos moleculares más precisos […]
Get in Touch With Our Customer Support
Our consultation service is available in several languages.
+49 (0) 381 80 113 - 416
Mon. – Fri. 7 a.m. – 8 p.m. CEST
Sat. 8 a.m. – 12 p.m. CEST